Home   


About Alferon
How it works
FAQ's
Product Brochure
Package Inserts
Alferon Access Program


 

 

About ALFERON N Injection®

ALFERON N Injection® [Interferon alfa-n3 (human leukocyte derived)] is the Company's registered trademark for its injectable formulation of Natural Alpha Interferon, approved by the U.S. Food and Drug Administration (FDA) for the intralesional treatment of refractory or recurring external condylomata acuminata in patients 18 years of age or older.

ALFERON N Injection® is the only highly purified, natural-source, multispecies alpha interferon product currently sold in the U.S. and is also approved for sale in Argentina.

Clinically Effective:

  • All warts disappeared in 54% of patients.3
  • No recurrence in 76% of complete responders at follow-up.3
  • Completely cleared 73% of all treated warts.3,4
  • No human antibodies to interferon alfa-n3 detected in clinical trails.3,4
  • Provides a spectrum of multiple alpha interferon subtypes.1,2

Well-tolerated

  • No surgery or caustics and resultant ulceration or scarring.
  • No specific post-treatment care necessary.4
  • The most common adverse effects (mild to moderate, transient flu-like symptoms) were comparable to placebo after 304 weeks of therapy.3.4
  • The majority of patients considered Alferon N Injection preferable to conventional therapy. 3.4

Please see the package insert for prescribing information.

References:
1 Baron S, Tyring SK, Fleischmann WR Jr, et al. The interferons: mechanisms of action and clinical applications. JAMA. 1991;226:1375-1383.
2 Antonelli, G, Current M, Turriziani O, Dianzani F. Neutralizing antibodies to interferon-µ: relative frequency in patients treated in different interferon preparations. J Infec. Dis. 1991;882-885
3 Data on file. Hemispherx Biopharma, Inc. Philadelphia, PA; 1988
4 Friedman-Kien AE, Eron LJ, Conant M, et al. Natural interferon alfa for treatment of condylomata acuminata. JAMA. 1988;259:533-538
 
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.